The novel biological agent, which affects about 1.4 out of every 100,000 people in country, ushers in a new era in the medical treatment of the illness, according to medical experts.
German pharmaceutical company Boehringer Ingelheim held ceremonies simultaneously on Saturday in Shanghai and Beijing to mark the entry into China of the first biological agent used to treat the rare and severe skin condition known as generalized pustular psoriasis (GPP).
The novel biological agent, which affects about 1.4 out of every 100,000 people in the country, ushers in a new era in the medical treatment of the illness, according to medical experts.
GPP is a rare skin condition that frequently has an abrupt onset. Along with the appearance of numerous pustules all over the body and skin reddening, patients also experience fever, chills, and itchy skin lesions. Generalized pustular psoriasis can cause complications and organ failures that are potentially fatal in severe cases.
The pathogenesis of the illness is closely connected to the signaling pathway of the cytokine IL-36 in the human body, according to Gu Jun, director of the dermatology division at Shanghai No. 10 People’s Hospital Affiliated with Tongji University.
According to him, the therapy inhibits the inflammatory signaling pathway of GPP and blocks the inflammatory response brought on by IL-36 in order to achieve rapid clearance of pustules and skin lesions.
“There was no proven treatment for GPP attacks. The traditional disease treatment’s deadlock has been broken by the novel therapy “Gao Xinghua, vice president and head of the dermatology division at the First Hospital of China Medical University, made the statement.
A rare and severe form of psoriasis known as generalized pustular psoriasis is characterised by the presence of sterile pustules. Although infantile and juvenile cases are also reported, the incidence is highest in people between the ages of 40 and 59.
In people with pure generalized pustular psoriasis without plaque psoriasis, the onset age is typically younger. Metabolic syndrome and polyarthritis are frequently linked with GPP.
In this activity, the inter professional team’s role in diagnosing and treating generalized pustular psoriasis is reviewed, along with its evaluation and treatment.